{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:32:03Z","timestamp":1789140723355,"version":"build-2803163510"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Chronic kidney disease (CKD), a serious complication of type 2 diabetes (T2D) increases the comorbid risk of cardiovascular disease (CVD) and end-stage kidney disease<\/jats:p><jats:p>(ESKD). Treatment guidelines recommend renin\u2013angiotensin blockade and antihyperglycemic treatment with metformin and sodium-glucose cotransporter 2 inhibitors (SGLT2is) as first-line treatment. We evaluated treatment initiation and discontinuation overall and in subgroups of T2D patients with incident CKD (incident cohort) and rates of clinical and economic outcomes in patients with T2D and any CKD (prevalent cohort).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective study of administrative claims in the USA between 1 January 2007 and 31 March 2019, we evaluated the proportion of patients with concomitant, newly initiated and discontinued use of antihypertensive [angiotensin-converting enzyme inhibitor (ACEi)\/angiotensin II receptor blockers (ARBs), steroidal mineralocorticoid receptor antagonists (sMRAs)] and antidiabetic [SGLT2is, dipeptidyl peptidase-4 inhibitors (DPP4is), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), insulin and sulfonylureas] medications, rates of clinical outcomes per 1000 person-years and mean total healthcare costs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 63\u2009127 and 326\u2009763 patients in the incident and prevalent CKD cohorts, respectively. Low initiation and high discontinuation rates were observed with 17.8% and 56.0% for ACEi\/ARBs, 1.3% and 66.0% for sMRAs, 2.5% and 65.0% for SGLT2is, 3.7% and 66.8% for DPP4is, 2.31% and 69.0% for GLP-1 RAs, 4% and 75.7% for insulin and 5.5% and 56.9% for sulfonylureas. Similar results were seen by subgroups. Rates of clinical outcomes ranged from 35.07 per 1000 person-years for all-cause mortality to 104.19 for ESKD, with rates of hospitalization ranging from 36.61 for kidney hospitalizations to 283.14 for all-cause hospitalizations. Among patients with comorbidities, higher clinical and economic outcomes were found.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results highlight high unmet needs of CKD and T2D, particularly subgroups of patients with multimorbid CVD, high-risk CKD (low estimated glomerular filtration rate or high urinary albumin:creatinine ratio) or rapidly progressing CKD. Low initiation and high discontinuation of recommended treatments suggest that adherence to guidelines for halting CKD progression is suboptimal. These high-risk patients may benefit from further treatment options to improve morbidity and mortality and reduce the economic burden.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ndt\/gfac140","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T14:24:20Z","timestamp":1649341460000},"page":"630-643","source":"Crossref","is-referenced-by-count":35,"title":["High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database"],"prefix":"10.1093","volume":"38","author":[{"given":"Linda","family":"Fried","sequence":"first","affiliation":[{"name":"VA Pittsburgh Healthcare System, University of Pittsburgh , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Schmedt","sequence":"additional","affiliation":[{"name":"Bayer AG , Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Folkerts","sequence":"additional","affiliation":[{"name":"Bayer AG , Wuppertal , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7588-1274","authenticated-orcid":false,"given":"Kevin","family":"Bowrin","sequence":"additional","affiliation":[{"name":"Bayer Plc , Reading , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanaya","family":"Raad","sequence":"additional","affiliation":[{"name":"Science, Aetion, Inc. , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Batech","sequence":"additional","affiliation":[{"name":"Science, Aetion, Inc. , Frankfurt am Main , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8204-911X","authenticated-orcid":false,"given":"Csaba","family":"Kovesdy","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Tennessee , Memphis, TN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"issue":"2 Suppl 2","key":"2023030115330998700_","first-page":"S12","article-title":"KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease","volume":"49","author":"Kidney Disease Outcomes Quality Initiaitve","year":"2007","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"2023030115330998700_","first-page":"1445","article-title":"Diabetic nephropathy\u2014a review of the natural history, burden, risk factors and treatment","volume":"96","author":"Ayodele","year":"2004","journal-title":"J Natl Med Assoc"},{"key":"2023030115330998700_","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1053\/j.ajkd.2019.09.003","article-title":"US Renal Data System 2019 annual data report: epidemiology of kidney disease in the United States","volume":"75","author":"Saran","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2023030115330998700_","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.2215\/CJN.11111016","article-title":"Diagnosis and management of type 2 diabetic kidney disease","volume":"12","author":"Doshi","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5 Suppl 3","key":"2023030115330998700_","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal disease","volume":"32","author":"Foley","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"2023030115330998700_","doi-asserted-by":"crossref","first-page":"e0199378","DOI":"10.1371\/journal.pone.0199378","article-title":"Anemia modifies the prognostic value of glycated hemoglobin in patients with diabetic chronic kidney disease","volume":"13","author":"Kuo","year":"2018","journal-title":"PLoS One"},{"key":"2023030115330998700_","volume-title":"Chapter 6: Healthcare Expenditures for Persons with CKD","author":"United States Renal Data System","year":"2017"},{"key":"2023030115330998700_","doi-asserted-by":"crossref","first-page":"vii2","DOI":"10.1093\/ndt\/gfg1072","article-title":"Epidemiology of cardiovascular risk in patients with chronic kidney disease","volume":"18","author":"Locatelli","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2023030115330998700_","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"2023030115330998700_","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","author":"de Boer","year":"2020","journal-title":"Kidney Int"},{"key":"2023030115330998700_","first-page":"CD007004","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2023030115330998700_","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.2215\/CJN.02690320","article-title":"Decision algorithm for prescribing SGLT2 inhibitors and GLP-1 receptor agonists for diabetic kidney disease","volume":"15","author":"Li","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023030115330998700_","doi-asserted-by":"crossref","first-page":"B10","DOI":"10.2337\/diacare.27.suppl_2.B10","article-title":"Who has diabetes? Best estimates of diabetes prevalence in the department of veterans affairs based on computerized patient data","volume":"27","author":"Miller","year":"2004","journal-title":"Diabetes Care"},{"key":"2023030115330998700_","first-page":"1506","article-title":"Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database","volume":"26","author":"Folkerts","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"2023030115330998700_","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/ckj\/sfaa200","article-title":"Chronic kidney disease progression among patients with type 2 diabetes identified in US administrative claims: a population cohort study","volume":"14","author":"Kovesdy","year":"2021","journal-title":"Clin Kidney J"},{"key":"2023030115330998700_","first-page":"907","article-title":"Development and validation of an electronic phenotyping algorithm for chronic kidney disease","volume":"2014","author":"Nadkarni","year":"2014","journal-title":"AMIA Annu Symp Proc"},{"key":"2023030115330998700_","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/ijcp.12640","article-title":"Estimated glomerular filtration rate progression in UK primary care patients with type 2 diabetes and diabetic kidney disease: a retrospective cohort study","volume":"69","author":"Cid Ruzafa","year":"2015","journal-title":"Int J Clin Pract"},{"key":"2023030115330998700_","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40273-015-0333-4","article-title":"Understanding adherence and prescription patterns using large-scale claims data","volume":"34","author":"Bjarnad\u00f3ttir","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"2023030115330998700_","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.2215\/CJN.03060319","article-title":"Association of acute increases in plasma creatinine after renin-angiotensin blockade with subsequent outcomes","volume":"14","author":"Fu","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023030115330998700_","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2023030115330998700_","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2023030115330998700_","doi-asserted-by":"crossref","first-page":"e1918169","DOI":"10.1001\/jamanetworkopen.2019.18169","article-title":"Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry","volume":"2","author":"Tuttle","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2023030115330998700_","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"2023030115330998700_","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc21-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142021","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"key":"2023030115330998700_","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"key":"2023030115330998700_","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2023030115330998700_","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfac140\/43858221\/gfac140.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/3\/630\/49352620\/gfac140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/3\/630\/49352620\/gfac140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T19:31:50Z","timestamp":1700422310000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/38\/3\/630\/6564744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,4,7]]},"published-print":{"date-parts":[[2023,2,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfac140","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3]]},"published":{"date-parts":[[2022,4,7]]}}}